RLN2

Summary

RLN2 (relaxin 2, HGNC:10027) is a protein-coding gene on chromosome 9p24.1, encoding Prorelaxin H2 (P04090). Relaxin is an ovarian hormone that acts with estrogen to produce dilatation of the birth canal in many mammals.

This gene encodes a member of the relaxin subfamily and insulin superfamily of peptide hormones. In humans there are three non-allelic relaxin genes. This gene encodes multiple protein isoforms, at least one of which undergoes proteolytic processing. This processing generates relaxin A and B chains that are linked by disulfide bonds to form the mature peptide hormone. This hormone plays a role in the male and female reproductive systems and was initially noted for its role in pregnancy. This protein also plays broader roles in the cardiovascular system, including in the regulation of blood pressure and control of heart rate, and data from animal models shows that this protein may have anti-fibrotic and cardioprotective effects.

Source: NCBI Gene 6019 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 43 total — 1 pathogenic
• MANE Select transcript: NM_134441

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10027
Approved symbol	RLN2
Name	relaxin 2
Location	9p24.1
Locus type	gene with protein product
Status	Approved
Aliases	H2, RLXH2, bA12D24.1.1, bA12D24.1.2
Ensembl gene	ENSG00000107014
Ensembl biotype	protein_coding
OMIM	179740
Entrez	6019

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000381627, ENST00000416837

RefSeq mRNA: 2 — MANE Select: NM_134441 NM_005059, NM_134441

CCDS: CCDS6460

Canonical transcript exons

ENST00000381627 — 2 exons

Exon	Start	End
ENSE00001865224	5304370	5304716
ENSE00003571259	5299864	5300444

Expression profiles

Bgee: expression breadth ubiquitous, 165 present calls, max score 92.74.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0680 / max 35.6209, expressed in 42 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
99815	0.0680	42

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endometrium epithelium	UBERON:0004811	92.74	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.30	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.75	gold quality
islet of Langerhans	UBERON:0000006	72.30	gold quality
right uterine tube	UBERON:0001302	67.66	gold quality
pituitary gland	UBERON:0000007	66.64	gold quality
adenohypophysis	UBERON:0002196	66.61	gold quality
granulocyte	CL:0000094	65.59	gold quality
endothelial cell	CL:0000115	64.48	silver quality
lymph node	UBERON:0000029	64.02	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	63.29	gold quality
pancreatic ductal cell	CL:0002079	61.42	silver quality
metanephros cortex	UBERON:0010533	60.17	gold quality
tibialis anterior	UBERON:0001385	60.10	silver quality
vermiform appendix	UBERON:0001154	60.09	gold quality
left testis	UBERON:0004533	59.89	gold quality
ventricular zone	UBERON:0003053	59.71	gold quality
testis	UBERON:0000473	59.56	gold quality
prostate gland	UBERON:0002367	59.42	gold quality
pancreas	UBERON:0001264	57.65	gold quality
pigmented layer of retina	UBERON:0001782	57.51	gold quality
right testis	UBERON:0004534	57.49	gold quality
caecum	UBERON:0001153	57.12	gold quality
spleen	UBERON:0002106	56.81	gold quality
mucosa of transverse colon	UBERON:0004991	56.78	gold quality
decidua	UBERON:0002450	56.55	gold quality
ileal mucosa	UBERON:0000331	55.93	silver quality
upper leg skin	UBERON:0004262	55.27	gold quality
deltoid	UBERON:0001476	54.47	silver quality
epithelium of nasopharynx	UBERON:0001951	54.40	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.22

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ESR1, FOXC1, NR3C1, PGR

miRNA regulators (miRDB)

23 targeting RLN2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-10395-5P	99.86	67.35	676
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-4643	99.49	67.63	1791
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-4263	99.18	69.25	2236
HSA-MIR-4711-5P	98.89	68.00	965
HSA-MIR-6818-5P	97.50	67.10	1167
HSA-MIR-3649	96.85	64.10	340
HSA-MIR-592	96.59	67.59	817
HSA-MIR-492	94.02	64.46	413
HSA-LET-7D-3P	89.01	66.89	93

Literature-anchored findings (GeneRIF, showing 40)

• Expression, purification and characterization of human prorelaxin-like-protein H2 in Escherichia coli (PMID:12198562)
• regulates fibrillin 2, but not fibrillin 1, mRNA and protein expression by human dermal fibroblasts and murine fetal skin (PMID:12590922)
• Relaxin stimulates new blood vessel formation and increases cytokine-containing lymphocyte number while maintaining endometrial connective tissue integrity. (PMID:15070778)
• No difference in bioactivity was detected between porcine relaxin-1 and recombinant human relaxin-2 in either mice or rats (PMID:15956696)
• Adenovirus-mediated delivery of human H2 preprorelaxin (hH2) to the brain is capable of producing bioactive relaxin that affects cardiovascular parameters (PMID:15956711)
• relaxin 2 can increase Cyclic AMP via Gs-adenylate cyclase pathway (PMID:15956719)
• Although all cell types expressed mRNA for the relaxin receptor (LGR7), only peripheral blood mononuclear cells responded to relaxin 2 at physiologic levels by increasing tumor necrosis factor-alpha and interleukin-1beta secretion (PMID:15956727)
• characterization of upregulated H2 relaxin gene expression during neuroendocrine differentiation of the human prostate cancer model, LNCaP (PMID:15956728)
• relaxin-like hormones appear to be present early during C-cell hyperplasia and potentially functional relaxin/INSL3 ligand-receptor systems are present in human medullary thyroid carcinoma tissues and cell lines (PMID:15956746)
• Relaxin is a potent antifibrotic hormone with a rapid-occurring efficacy that may have therapeutic potential for hypertensive disease. (PMID:15967869)
• study provides the first account of a potential role of H2 relaxin in prostate tumor development (PMID:16049981)
• The structural-functional organization of the adenylyl cyclase signaling mechanism due to the action of human relaxin 2 was deciphered. (PMID:16580233)
• Relaxin enhances the oncogenic potential and acts as novel endocrine modulator of invasiveness in human thyroid carcinoma cells. (PMID:16877360)
• Relaxin signaling plays a role in prostate cancer progression. (PMID:17363522)
• Correlation between fibrinogen levels and relaxin expression. Relaxin may exert its cardioprotective properties after pathologic fibrinogen increase. May be affected by diabetes. Cardiovascular risk may increase in women with aberrant relaxin function. (PMID:17616862)
• Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. (PMID:17653089)
• results suggest that relaxin may promote the invasive potential of early placental EVTs through up-regulating MMP-2, -9 mRNAs and down-regulating TIMP-1 mRNA in EVTs. (PMID:18236174)
• Data show taht relaxin causes mast cell inhibition and reduced ventricular arrhythmias in a swine model of acute myocardial infarction. (PMID:18345514)
• analysis of truncated human relaxin-2 and -3 (H2 and H3) relaxin peptides and their binding and cAMP activities on RXFP1, RXFP2, and RXFP3 (PMID:18434306)
• Relaxin 2 was expressed in E. coli BL21 (DE3), several forms of the protein were made. One species had the expected molecular weight (19,084 Da). A 2ndspecies observed had a molecular weight of 21,244 Da. A 3rd species had a molecular weight of 17,118 Da (PMID:18474430)
• Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1. (PMID:18723073)
• RLXH2 inhibits myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. (PMID:19073841)
• Study have identified a positive auto-regulatory loop of human relaxin-2 expression which involves GR and relaxin/GR binding to half-GREs in the relaxin-2 promoter. (PMID:19289144)
• Women homozygous for prevalent SNPs in the RLN2 gene may have a genetic susceptibility for preterm birth. (PMID:20023247)
• Stable RLN2 transfectants secreted enhanced levels of bioactive MMP2 which contributed to the increased collagenolytic activity and in vitro invasiveness into collagen matrix by human thyroid cancer cells. (PMID:21493587)
• The mean serum relaxin concentrations for athletes with anterior cruciate ligament tears was significantly higher than that for those without anterior cruciate ligament tears. (PMID:21737831)
• The combined data indicate RLN2 overexpression is frequent in prostate cancer patients (PMID:21789713)
• The minimal active structure of human relaxin-2. (PMID:21878627)
• Relaxin significantly increased the MMP-1 and MMP-8 expression in a time-dependent manner in human periodontal ligament cells in vitro. (PMID:22141456)
• H2-RLX could give play to the antifibrotic effects by repressing the fibroblast proliferation and transdifferentiation for myofibroblast in systemic sclerosis. (PMID:22152813)
• Recombinant H2 relaxin selectively inhibits apoptosis by down-regulating caspse-3 expression and induces proliferation in cultured human leiomyoma cells without affecting apoptosis or proliferation in normal myometrial cells. (PMID:22226177)
• relaxin-2 and its receptors RXFP1 and RXFP2 are expressed in GSV and their expression is significantly decreased in varicose GSV (PMID:22737225)
• The role of the pleiotropic peptide hormone, human relaxin-2 in cancer. [Review] (PMID:22855207)
• Skeletal myoblasts engineered to express RLN2 promote myocardial viability and performance improvement post-myocardial infarction. (PMID:22949764)
• Identification of key residues essential for the structural fold and receptor selectivity within the A-chain of human gene-2 (H2) relaxin (PMID:23024363)
• Our data support a novel role for the RLN2 ligand-receptor system at the ocular surface and in the lacrimal apparatus as a potential future therapeutic during wound healing at the ocular surface. (PMID:23111608)
• serum relaxin-2 may have a role in progression esophageal squamous cell carcinoma (PMID:23613637)
• overexpression of relaxin-2 protein in hepatocellular carcinoma (HCC) tissues is of predictive value on tumor progression and poor prognosis. (PMID:23661524)
• relaxin may promote the proliferation, invasion and metastasis of osteosarcoma cells by regulating the expression of MMP-9 and facilitating ECM degradation. (PMID:23661525)
• This review provides information on the structure and function of relaxin and its receptors. Furthermore, we present evidence of the involvement of these elements in the process of cancerogenesis. (PMID:23668059)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rln1	ENSMUSG00000039097
rattus_norvegicus	Rln1	ENSRNOG00000060867

Paralogs (3): RLN1 (ENSG00000107018), INSL6 (ENSG00000120210), INSL4 (ENSG00000120211)

Protein

Protein identifiers

Prorelaxin H2 — P04090 (reviewed: P04090)

All UniProt accessions (2): P04090, H0Y5M9

UniProt curated annotations — full annotation on UniProt →

Function. Relaxin is an ovarian hormone that acts with estrogen to produce dilatation of the birth canal in many mammals. May be involved in remodeling of connective tissues during pregnancy, promoting growth of pubic ligaments and ripening of the cervix.

Subunit / interactions. Heterodimer of a B chain and an A chain linked by two disulfide bonds.

Subcellular location. Secreted.

Tissue specificity. Isoform 1 is expressed in the ovary during pregnancy. Also expressed in placenta, decidua and prostate. Isoform 2 is relatively abundant in placenta. It is in much lower abundance in the prostate gland. Not detected in the ovary.

Similarity. Belongs to the insulin family.

Isoforms (2)

UniProt ID	Names	Canonical?
P04090-1	1	yes
P04090-2	2

RefSeq proteins (2): NP_005050, NP_604390* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016179	Insulin-like	Domain
IPR022352	Ins/IGF/rlx	Family
IPR022353	Insulin_CS	Conserved_site
IPR022421	Relaxin	Family
IPR036438	Insulin-like_sf	Homologous_superfamily
IPR051042	Repro_Hormone_Insulin-like	Family

Pfam: PF00049

UniProt features (16 total): helix 4, disulfide bond 3, peptide 2, sequence variant 2, splice variant 2, signal peptide 1, propeptide 1, modified residue 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6RLX	X-RAY DIFFRACTION	1.5
2MV1	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P04090-F1	62.52	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 162

Disulfide bonds (3): 35–172, 47–185, 171–176

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-418555	G alpha (s) signalling events
R-HSA-444821	Relaxin receptors

MSigDB gene sets: 89 (showing top): YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_10, CCAWYNNGAAR_UNKNOWN, GOZGIT_ESR1_TARGETS_DN, GOBP_POSITIVE_REGULATION_OF_VASCULATURE_DEVELOPMENT, GGGTGGRR_PAX4_03, REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS, GOBP_BLOOD_VESSEL_MORPHOGENESIS, GOBP_MULTI_MULTICELLULAR_ORGANISM_PROCESS, SASAKI_ADULT_T_CELL_LEUKEMIA, GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, GOMF_SIGNALING_RECEPTOR_BINDING, CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN, GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_VASCULATURE_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS

GO Biological Process (5): female pregnancy (GO:0007565), positive regulation of gene expression (GO:0010628), positive regulation of angiogenesis (GO:0045766), regulation of catalytic activity (GO:0050790), signal transduction (GO:0007165)

GO Molecular Function (1): hormone activity (GO:0005179)

GO Cellular Component (1): extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
GPCR downstream signalling	1
Peptide ligand-binding receptors	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
multi-organism reproductive process	1
multi-multicellular organism process	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
angiogenesis	1
regulation of angiogenesis	1
positive regulation of vasculature development	1
catalytic activity	1
regulation of molecular function	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
receptor ligand activity	1
cellular anatomical structure	1

Protein interactions and networks

STRING

350 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RLN2	RXFP1	Q9HBX9	998
RLN2	RXFP2	Q8WXD0	978
RLN2	RLN3	Q8WXF3	940
RLN2	INSL5	Q9Y5Q6	938
RLN2	INSL3	P51460	918
RLN2	INSL4	Q14641	917
RLN2	RXFP3	Q9NSD7	865
RLN2	RXFP4	Q8TDU9	834
RLN2	INS	P01308	753
RLN2	LGR6	Q9HBX8	718
RLN2	INSL6	Q9Y581	559
RLN2	C1QTNF8	P60827	544
RLN2	MBL2	P11226	497
RLN2	X6REF7	X6REF7	490
RLN2	SFTPA2	P07714	469

IntAct

5 interactions, top by confidence:

A	B	Type	Score
MCTS1	DENR	psi-mi:“MI:0914”(association)	0.870
RLN1	RTL8C	psi-mi:“MI:0914”(association)	0.350
RLN2	AIP	psi-mi:“MI:0914”(association)	0.350
RLN2	ACTN3	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): COL14A1 (Affinity Capture-MS), TENM3 (Affinity Capture-MS), MIPEP (Affinity Capture-MS), RLN2 (Affinity Capture-MS), PCYOX1L (Affinity Capture-MS), AIP (Affinity Capture-MS), RLN2 (Affinity Capture-MS), POTEE (Affinity Capture-MS), COL12A1 (Affinity Capture-MS), TUBA3C (Affinity Capture-MS), ACTN3 (Affinity Capture-MS)

ESM2 similar proteins: A5A6J6, O35417, P01172, P01213, P01214, P01347, P01348, P04090, P04808, P05408, P06300, P09681, P12961, P13207, P17640, P19884, P20800, P22389, P22969, P23943, P27682, P33745, P45644, P47932, P48143, P51453, P51454, P51455, P51456, P56943, P69155, P69156, P69157, Q14641, Q1RMJ9, Q32L79, Q5CZK5, Q5CZK6, Q60478, Q64171

Diamond homologs: P01347, P01348, P04090, P04808, P19884, P22969, P47932, P51453, P51454, P51455, P51456, Q64171, Q9MYK8, Q9TRM8, P11184, P11185, Q14641, Q5CZK6, Q7M3C4, Q9Y581

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
RLN2	up-regulates	RXFP1	binding
RLN2	up-regulates	RXFP2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	35
Likely benign	6
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
253633	GRCh37/hg19 9p24.3-13.1(chr9:163131-38763958)x3	Pathogenic

SpliceAI

290 predictions. Top by Δscore:

Variant	Effect	Δscore
9:5300442:TTT:T	acceptor_gain	0.9900
9:5300443:TT:T	acceptor_gain	0.9900
9:5300445:C:CC	acceptor_gain	0.9900
9:5300440:AATTT:A	acceptor_gain	0.9800
9:5300441:ATTTC:A	acceptor_loss	0.9800
9:5300442:TTTCT:T	acceptor_loss	0.9800
9:5300443:TTCTG:T	acceptor_loss	0.9800
9:5300444:TCTGT:T	acceptor_loss	0.9800
9:5300445:CTGTT:C	acceptor_loss	0.9800
9:5300446:T:G	acceptor_loss	0.9800
9:5304132:T:TA	donor_gain	0.9800
9:5300441:ATTT:A	acceptor_gain	0.9700
9:5304094:A:AC	donor_gain	0.9700
9:5304095:C:CC	donor_gain	0.9700
9:5304402:T:TA	donor_gain	0.9600
9:5300454:T:C	acceptor_gain	0.9500
9:5300448:T:TC	acceptor_gain	0.9400
9:5303990:T:A	donor_gain	0.9400
9:5303492:A:C	donor_gain	0.9200
9:5304089:G:GA	donor_gain	0.9200
9:5300452:A:C	acceptor_gain	0.8900
9:5304364:TCTCA:T	donor_loss	0.8800
9:5304365:CTCA:C	donor_loss	0.8800
9:5304366:TCACC:T	donor_loss	0.8800
9:5304367:CACCT:C	donor_loss	0.8800
9:5304369:C:CG	donor_loss	0.8800
9:5300448:T:C	acceptor_gain	0.8700
9:5301244:T:A	donor_gain	0.8700
9:5300454:T:TC	acceptor_gain	0.8600
9:5300453:T:C	acceptor_gain	0.8500

AlphaMissense

1212 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:5300133:C:A	G175C	0.985
9:5300129:C:G	C176S	0.983
9:5300130:A:T	C176S	0.983
9:5300144:C:G	C171S	0.982
9:5300145:A:T	C171S	0.982
9:5304441:C:G	C47S	0.982
9:5304442:A:T	C47S	0.982
9:5300141:C:G	C172S	0.981
9:5300142:A:T	C172S	0.981
9:5304477:C:G	C35S	0.980
9:5304478:A:T	C35S	0.980
9:5304441:C:T	C47Y	0.979
9:5300130:A:G	C176R	0.974
9:5304477:C:T	C35Y	0.974
9:5300101:G:C	C185W	0.973
9:5304442:A:G	C47R	0.973
9:5300145:A:G	C171R	0.970
9:5300102:C:T	C185Y	0.967
9:5300141:C:T	C172Y	0.967
9:5304477:C:A	C35F	0.967
9:5304440:G:C	C47W	0.966
9:5300103:A:G	C185R	0.964
9:5304459:C:G	R41P	0.963
9:5300102:C:G	C185S	0.962
9:5300103:A:T	C185S	0.962
9:5300129:C:T	C176Y	0.962
9:5300143:A:C	C171W	0.962
9:5300132:C:T	G175D	0.960
9:5300142:A:G	C172R	0.960
9:5304441:C:A	C47F	0.959

dbSNP variants (sampled 300 via entrez): RS1000089856 (9:5335792 T>C), RS1000180247 (9:5339401 G>C,T), RS1000233925 (9:5339734 A>C,G), RS1000238940 (9:5308322 C>G), RS1000246424 (9:5333175 A>G,T), RS1000250481 (9:5301742 G>A,C,T), RS1000291243 (9:5308680 A>C), RS1000351584 (9:5325344 GA>G,GAA), RS1000422419 (9:5329326 A>AAG), RS1000585220 (9:5315323 G>A,C), RS1000596827 (9:5307304 GATAGATGA>G), RS1000637530 (9:5312139 T>C), RS1000701774 (9:5333298 A>C), RS1000943144 (9:5317645 TTACAAA>T), RS1000956820 (9:5326294 G>C)

Disease associations

OMIM: gene MIM:179740 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	increases expression, affects cotreatment, decreases expression	3
Estradiol	affects reaction, affects expression, decreases reaction, increases expression	3
Valproic Acid	affects expression, increases expression	2
methylmercuric chloride	decreases expression	1
propionaldehyde	increases expression	1
decabromobiphenyl ether	affects expression	1
butyraldehyde	increases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
Fulvestrant	decreases reaction, increases expression	1
Vorinostat	increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Calcitriol	decreases expression, affects cotreatment	1
Carbamazepine	affects expression	1
Cisplatin	decreases expression	1
Dimethyl Sulfoxide	affects expression	1
Methylmercury Compounds	decreases expression	1
Silicon Dioxide	decreases expression	1
Testosterone	affects cotreatment, decreases expression	1
Tetrachlorodibenzodioxin	decreases reaction, increases expression, decreases expression	1
Thimerosal	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases expression	1
Cadmium Chloride	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.